Peptides and Sexual Function: Research, Claims and Gaps

Original Posted on Substack | Nov 7, 2026

Search for “peptides for libido” and you will find a crowded market of claims. Some come from clinical trials. Many come from vendor pages, forums and influencers, and they blur the line between an approved prescription drug, a small early study and an animal result. This piece separates them. It covers four compounds that come up most often: bremelanotide (PT-141), melanotan II, kisspeptin and oxytocin. It does not recommend using any of them, and it gives no dosing.

The short version

One of these has gone through large, controlled trials for a sexual-function indication and is approved: bremelanotide, for a specific group of women.
Melanotan II has a small, old human study and a record of safety warnings. It is not approved for any use.
Kisspeptin has produced interesting brain-imaging findings in a small group of healthy men. It has no clinical trial for sexual dysfunction behind it.
Oxytocin has a large literature on social behavior and a thin, mixed one on sexual function.
Active research is mostly new uses of bremelanotide, not new compounds.
A vendor page that blends these four into “peptides for sex” is describing four very different evidence bases as one.

Bremelanotide (PT-141): the approved one, with narrow limits

What it is: A melanocortin receptor agonist. The FDA approved it as Vyleesi on June 21, 2019, for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), a condition defined by low desire that causes distress.

Evidence: The approval rests on two identical 24-week, randomized, double-blind, placebo-controlled phase 3 trials in women aged 19 to 56 in the US and Canada, with an optional 52-week open-label extension. The FDA’s trial summary reports that desire scores improved by about 0.5 to 0.6 points on the scale used, compared with about 0.2 for placebo, and that distress scores fell by about 0.7 points, compared with about 0.4 for placebo. These are modest average changes, and they are what a regulator judged to be enough for approval in that population.

What the trials also found: Nausea was reported by 40.0% of women on the drug versus 1.3% on placebo, flushing by 20.3% versus 0.3%, headache by 11.3% versus 1.9% and vomiting by 4.8% versus 0.2%. The label warns of a temporary rise in blood pressure and fall in heart rate after each dose, darkening of the gums and of skin on the face and breasts, and nausea that can be severe.

What the evidence does not cover: All trial participants were women, and about 86% were White, so the FDA notes that results for other groups cannot be fully assessed. The approval is for one indication in one population. It does not establish benefit in men or in other situations, and it says nothing about unregulated products sold under the same name.

Grade (suggested, adjust to your scale): A for the approved indication only.

Melanotan II: an old small study and a record of warnings

What it is: A synthetic melanocortin analogue originally studied for tanning. It is not approved by the FDA for any use.

Evidence: The human sexual-function data come largely from a small double-blind, placebo-controlled crossover study published in 2000 (Wessells and colleagues, International Journal of Impotence Research). In 20 men with erectile dysfunction, 17 had erections without sexual stimulation, and increased desire was reported after 13 of 19 doses versus 4 of 21 placebo doses. Nausea and yawning were the most frequent side effects, and about 13% had severe nausea at the higher dose tested. The authors called for more investigation. That study is more than 25 years old, small, and short.

Safety record: The Skin Cancer Foundation, in a July 2026 statement, discouraged the use of melanotan II and other unapproved tanning agents, citing published case reports of melanoma, rapid changes in moles, systemic toxicity and muscle damage. The Foundation says case reports cannot establish causation, and the full short- and long-term effects are unknown. The UK’s MHRA has said for years that melanotan products sold there are unlicensed and have not been tested for safety, quality or effectiveness.

Grade (suggested): C or lower. A 2000 pilot study is not a basis for confidence, and the safety signals are real.

Kisspeptin: intriguing biology, no clinical case yet

What it is: A naturally occurring peptide that sits near the top of the reproductive hormone cascade.

Evidence: A 2017 placebo-controlled crossover study in JCI Insight gave intravenous kisspeptin-54 to 29 healthy heterosexual men, aged about 25, while they underwent brain imaging and viewed sexual, couple-bonding, negative and neutral images. Kisspeptin increased activity in some brain regions involved in sexual and emotional processing, and the size of one reward-region response correlated with lower sexual aversion scores. It raised luteinizing hormone but did not change testosterone, oxytocin or cortisol.

What it does not show: The authors list their own limits: a small sample of young heterosexual men, intravenous dosing that does not mimic natural pulsatile release, correlational links between brain activity and questionnaires, and significant effects in only some regions. The study measured brain responses, not sexual function or any clinical outcome. The authors suggest future research in reproductive disorders and in psychosexual problems, and they say so as a possibility, not a finding. A brain-imaging result in healthy volunteers is not evidence that a product will help anyone.

Grade (suggested): C. Early human physiology.

Oxytocin: a lot of research, little of it on sexual function

What it is: A hormone and neuropeptide best known for roles in labor, lactation and social bonding.

Evidence: A 2021 systematic review in Sexual Medicine (Cera and colleagues) looked at whether blood or saliva oxytocin levels track sexual arousal and orgasm. It included 13 studies, about 325 participants in total, published between 1969 and 2019, with varied designs. Most found oxytocin higher around orgasm or ejaculation, while the arousal findings were mixed. The authors call their hypotheses tentative and ask for standardized stimuli and objective measures of arousal.

Important limit: That review excluded studies of intranasal oxytocin. It tells us how the body’s own oxytocin behaves, not whether a nasal spray improves sexual function, and I did not verify the results of intranasal treatment trials for this piece. Higher oxytocin during sex does not mean taking oxytocin improves sex.

Grade (suggested): C for any sexual-function claim.

What is being studied now

Nothing new has emerged as a late-stage peptide drug for sexual function that I could find. The current activity is mostly new uses and mechanism work for bremelanotide, plus early research on other peptides.

Bremelanotide for men, combined with an erectile dysfunction pill. In June 2024, Palatin announced an open-label phase 2 study of bremelanotide co-administered with a PDE5 inhibitor, planned for about 50 men whose erectile dysfunction did not respond adequately to a PDE5 inhibitor alone. The company said topline data were expected by the end of 2024. I found no reported results, so whether the study finished, and what it found, is unknown. This is company information, not a published result.
How bremelanotide may work in women. A 2022 Journal of Clinical Investigation study used brain imaging in 31 premenopausal women with low desire. More women reported increased desire within 24 hours after the drug than after placebo (21 versus 8), and the authors suggest the drug may reduce self-consciousness during sexual stimulation. It was funded by the drug’s manufacturer, tested single doses, and studied only premenopausal heterosexual women, so it is a mechanism study, not new proof of benefit.
Another bremelanotide trial. A phase 3 bridging trial in premenopausal women with HSDD is registered on ClinicalTrials.gov (NCT04943068). We could not retrieve its details, so we cannot say who is running it, where, or its status.
Kisspeptin and oxytocin. We found no newer human trials for sexual function beyond the work described above. Absence of a result in our search is not proof none exist; check ClinicalTrials.gov before citing.

The pattern is worth noticing: the compounds with the most credible activity are ones already studied in controlled trials, and the research-chemical “next generation” products promoted online usually have no trial behind them at all.

Common claims, and what the evidence supports

Claim you may see	What the evidence shows
“PT-141 is FDA approved.”	True for one indication in premenopausal women with HSDD. It does not cover other uses or other people.
“Clinically proven to boost desire.”	The approved drug showed a small average improvement over placebo in one population, with frequent nausea and flushing.
“Melanotan II treats ED.”	A 20-man study from 2000 showed erections. It is old and small, and safety concerns are documented.
“Kisspeptin improves libido.”	A brain-imaging study in 29 healthy men. No clinical outcome.
“Oxytocin boosts arousal.”	Body oxytocin rises around orgasm in several studies. That does not show a supplement works.
“Pharmaceutical-grade, tested for purity.”	A claim about a product, not about the compound. Ask for a certificate tied to the lot, and see our coverage of why a single purity number can mislead.

Where the research-chemical market fits

The gap between the approved drug and the products sold online is the main point. Vyleesi comes from a manufacturer that ran controlled trials and submitted to FDA review. A vial sold as “PT-141” or “melanotan” online has no such record. Its identity, purity and sterility are whatever the seller and a testing lab say. As covered in our recent Top 10, third-party testing results on the same product can differ widely between labs, and a large preprint found wide variability across vendors. Research-use-only labeling does not change the clinical evidence. A recent Peptides Weekly review summarizes US rules as treating intended use as what matters, with research-use-only wording not overriding evidence of marketing for human use; check FDA’s own guidance before relying on that.

What to take from this

Ask which compound a claim is about, and what kind of evidence sits behind it: an approved-drug trial, a small early study, a brain scan or an animal result.
Check the population. Evidence in premenopausal women does not carry over to men, and a study in healthy men does not carry over to anyone with a condition.
Treat side-effect data as part of the evidence, not an afterthought. In the bremelanotide trials, nausea affected roughly four in ten women on the drug.
Treat sexual-health concerns as medical questions for a licensed clinician. This article is not medical advice, a recommendation to use any compound, or a guide to sourcing one.

Evidence note: Bremelanotide data come from the FDA’s trial summary, not the full label. The melanotan II trial, the kisspeptin study and the oxytocin review were read through summaries and abstracts as available, not as full papers. I did not verify the compounding status of any of these four in the US, so check the FDA’s current lists before citing it. Safety statements about melanotan II come from case reports and advocacy or regulator warnings, which show concern but not cause.

Sources: